Keywords
Last Name
Institution

JEFFREY A JONES

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Urology
DivisionUrology
Address2002 HOLCOMBE BLVD
HOUSTON TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Space Medicine
    DivisionCenter for Space Medicine


    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Jul 17. PMID: 28714866.
      View in: PubMed
    2. Jones JA. Oxidative stress in bicuspid aortic valve-related aortopathy: Hand-me-downs and yoga pants. J Thorac Cardiovasc Surg. 2017 Jun 17. PMID: 28689786.
      View in: PubMed
    3. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 Apr 10. PMID: 28397242.
      View in: PubMed
    4. Guinn D, Lehman A, Fabian C, Yu L, Maddocks K, Andritsos LA, Jones JA, Flynn JM, Jaglowski SM, Woyach JA, Byrd JC, Johnson AJ. The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. Cancer Med. 2017 Mar 15. PMID: 28299881.
      View in: PubMed
    5. Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar; 4(3):e114-e126. PMID: 28257752.
      View in: PubMed
    6. Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017 Feb 21. PMID: 28223277.
      View in: PubMed
    7. Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC. BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017 Feb 13; JCO2016702282. PMID: 28418267.
      View in: PubMed
    8. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct; 17(10):1409-1418. PMID: 27637985.
      View in: PubMed
    9. Flinn IW, Ruppert AS, Harwin W, Waterhouse D, Papish S, Jones JA, Hainsworth J, Byrd JC. A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. Am J Hematol. 2016 Oct; 91(10):1020-5. PMID: 27387131.
      View in: PubMed
    10. Awan FT, Jones JA, Maddocks K, Poi M, Grever MR, Johnson A, Byrd JC, Andritsos LA. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. Ann Hematol. 2016 Jun; 95(7):1137-43. PMID: 27118540.
      View in: PubMed
    11. Jones JA. Editorial Commentary: Understanding Marfan syndrome, or "how not to invent the light bulb". Trends Cardiovasc Med. 2016 Jul; 26(5):429-32. PMID: 27013137; PMCID: PMC4912448 [Available on 07/01/17].
    12. Maddocks K, Jones JA. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. Semin Oncol. 2016 Apr; 43(2):251-9. PMID: 27040703.
      View in: PubMed
    13. Maddocks K, Hertlein E, Chen TL, Wagner AJ, Ling Y, Flynn J, Phelps M, Johnson AJ, Byrd JC, Jones JA. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2016 Sep; 57(9):2212-5. PMID: 26764527.
      View in: PubMed
    14. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):323-32. PMID: 26641137; PMCID: PMC4862586 [Available on 07/28/16].
    15. Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol. 2015 Nov; 90(11):967-9. PMID: 26202978.
      View in: PubMed
    16. Renaud L, Harris LG, Mani SK, Kasiganesan H, Chou JC, Baicu CF, Van Laer A, Akerman AW, Stroud RE, Jones JA, Zile MR, Menick DR. HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis. Circ Heart Fail. 2015 Nov; 8(6):1094-104. PMID: 26371176.
      View in: PubMed
    17. Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. JAMA Oncol. 2015 Aug; 1(5):684-6. PMID: 26182170.
      View in: PubMed
    18. Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015 Aug 13; 126(7):842-50. PMID: 26116658.
      View in: PubMed
    19. Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Hypermorphic mutation of phospholipase C, ?2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015 Jul 2; 126(1):61-8. PMID: 25972157.
      View in: PubMed
    20. McDonald LT, Russell DL, Kelly RR, Xiong Y, Motamarry A, Patel RK, Jones JA, Watson PM, Turner DP, Watson DK, Soloff AC, Findlay VJ, LaRue AC. Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Neoplasia. 2015 May; 17(5):434-48. PMID: 26025666.
      View in: PubMed
    21. Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA. Jumping translocations, a novel finding in chronic lymphocytic leukaemia. Br J Haematol. 2015 Jul; 170(2):200-7. PMID: 25891862.
      View in: PubMed
    22. Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2015 Jun; 169(5):701-10. PMID: 25847298.
      View in: PubMed
    23. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr; 1(1):80-7. PMID: 26182309.
      View in: PubMed
    24. Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA. Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015 Oct; 56(10):2834-40. PMID: 25669927.
      View in: PubMed
    25. Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). Am J Hematol. 2015 Apr; 90(4):327-33. PMID: 25639448; PMCID: PMC4552311.
    26. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Apr 16; 125(16):2497-506. PMID: 25700432; PMCID: PMC4400288.
    27. Cohen JB, Ruppert AS, Heerema NA, Andritsos LA, Jones JA, Porcu P, Baiocchi R, Christian BA, Byrd JC, Flynn J, Penza S, Devine SM, Blum KA. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015 May; 15(5):278-285.e1. PMID: 25660723.
      View in: PubMed
    28. Andritsos LA, Dunavin N, Lozanski G, Jones JA, Blachly JS, Lucas DM, Byrd JC, Kraut E, Grever MR. Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. Haematologica. 2015 Jan; 100(1):e18-20. PMID: 25361945; PMCID: PMC4281329.
    29. Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood. 2015 Jan 8; 125(2):284-95. PMID: 25293770; PMCID: PMC4287637.
    30. Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun; 6(3):749-55. PMID: 24594909; PMCID: PMC4011919.
    31. Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KA. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014 Jun 1; 120(11):1677-85. PMID: 24578014; PMCID: PMC4291121.
    32. Zile MR, Baicu CF, Stroud RE, Van Laer AO, Jones JA, Patel R, Mukherjee R, Spinale FG. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail. 2014 Mar 1; 7(2):340-50. PMID: 24395927; PMCID: PMC3961496.
    33. Jones JA, Byrd JC. How will B-cell-receptor-targeted therapies change future CLL therapy? Blood. 2014 Mar 6; 123(10):1455-60. PMID: 24394667; PMCID: PMC3945859.
    34. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan; 15(1):48-58. PMID: 24332241; PMCID: PMC4134524.
    35. Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. Am J Hematol. 2014 Jan; 89(1):19-24. PMID: 23959599; PMCID: PMC4150545.
    36. Eckhouse SR, Logdon CB, Oelsen JM, Patel RK, Rice AD, Stroud RE, Wince WB, Mukherjee R, Spinale FG, Ikonomidis JS, Jones JA. Reproducible porcine model of thoracic aortic aneurysm. Circulation. 2013 Sep 10; 128(11 Suppl 1):S186-93. PMID: 24030405; PMCID: PMC3840947.
    37. Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood. 2013 Nov 7; 122(19):3308-16. PMID: 24009233; PMCID: PMC3953089.
    38. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 Oct 10; 122(15):2539-49. PMID: 23886836; PMCID: PMC3795457.
    39. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74. PMID: 23810245; PMCID: PMC4180513.
    40. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4; 369(1):32-42. PMID: 23782158; PMCID: PMC3772525.
    41. Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JC. Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma. 2013 Dec; 54(12):2654-9. PMID: 23547837; PMCID: PMC3766417.
    42. Eckhouse SR, Akerman AW, Logdon CB, Oelsen JM, O'Quinn EC, Nadeau EK, Stroud RE, Mukherjee R, Jones JA, Spinale FG. Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg. 2013 Jan; 145(1):267-275, 277.e1-4; discussion 275-7. PMID: 23102905; PMCID: PMC3602970.
    43. Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LA. Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. Br J Haematol. 2012 Oct; 159(1):82-7. PMID: 22831395; PMCID: PMC3719859.
    44. Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL, Yeh YY, Andritsos L, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JC. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 2012 Aug 9; 120(6):1262-73. PMID: 22740450; PMCID: PMC3418721.
    45. Ball CG, Kirkpatrick AW, Williams DR, Jones JA, Polk JD, Vanderploeg JM, Talamini MA, Campbell MR, Broderick TJ. Prophylactic surgery prior to extended-duration space flight: is the benefit worth the risk? Can J Surg. 2012 Apr; 55(2):125-31. PMID: 22564516; PMCID: PMC3310768.
    46. Jones JA, Kraut EH, Deam D, Byrd JC, Grever MR. Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia. Leuk Lymphoma. 2012 Mar; 53(3):490-1. PMID: 22165992.
      View in: PubMed
    47. Jaglowski S, Jones JA. Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011 Sep; 11(9):1379-90. PMID: 21929312; PMCID: PMC4341916.
    48. Epperly MW, Wang H, Jones JA, Dixon T, Montesinos CA, Greenberger JS. Antioxidant-chemoprevention diet ameliorates late effects of total-body irradiation and supplements radioprotection by MnSOD-plasmid liposome administration. Radiat Res. 2011 Jun; 175(6):759-65. PMID: 21466381; PMCID: PMC3119545.
    49. Opperman RA, Waldie JM, Natapoff A, Newman DJ, Jones JA. Probability of spacesuit-induced fingernail trauma is associated with hand circumference. Aviat Space Environ Med. 2010 Oct; 81(10):907-13. PMID: 20922881.
      View in: PubMed
    50. Jones JA, Fayad LE, Elting LS, Rodriguez MA. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2010 Sep; 51(9):1649-57. PMID: 20807093.
      View in: PubMed
    51. Jones JA, Zavadzkas JA, Chang EI, Sheats N, Koval C, Stroud RE, Spinale FG, Ikonomidis JS. Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J Thorac Cardiovasc Surg. 2010 Sep; 140(3):653-9. PMID: 20219212; PMCID: PMC2901416.
    52. Woyach JA, Heerema NA, Zhao J, McFaddin A, Stark A, Lin TS, Andritsos LA, Blum KA, Flynn JM, Jones JA, Byrd JC. Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. Br J Haematol. 2010 Mar; 148(5):754-9. PMID: 20015097; PMCID: PMC2902554.
    53. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009 Dec 10; 27(35):6012-8. PMID: 19826119; PMCID: PMC2793044.
    54. Whitson PA, Pietrzyk RA, Jones JA, Nelman-Gonzalez M, Hudson EK, Sams CF. Effect of potassium citrate therapy on the risk of renal stone formation during spaceflight. J Urol. 2009 Nov; 182(5):2490-6. PMID: 19765769.
      View in: PubMed
    55. Scheuring RA, Mathers CH, Jones JA, Wear ML. Musculoskeletal injuries and minor trauma in space: incidence and injury mechanisms in U.S. astronauts. Aviat Space Environ Med. 2009 Feb; 80(2):117-24. PMID: 19198198.
      View in: PubMed
    56. Jones JA, Ciftcioglu N, Schmid JF, Barr YR, Griffith D. Calcifying nanoparticles (nanobacteria): an additional potential factor for urolithiasis in space flight crews. Urology. 2009 Jan; 73(1):210.e11-3. PMID: 18718644.
      View in: PubMed
    57. Jones JA, Cherian SF, Barr YR, Stocco A. Medullary sponge kidney and urinary calculi: aeromedical concerns. Aviat Space Environ Med. 2008 Jul; 79(7):707-11. PMID: 18619133.
      View in: PubMed
    58. Baisden DL, Beven GE, Campbell MR, Charles JB, Dervay JP, Foster E, Gray GW, Hamilton DR, Holland DA, Jennings RT, Johnston SL, Jones JA, Kerwin JP, Locke J, Polk JD, Scarpa PJ, Sipes W, Stepanek J, Webb JT. Human health and performance for long-duration spaceflight. Aviat Space Environ Med. 2008 Jun; 79(6):629-35. PMID: 18581950.
      View in: PubMed
    59. Jones JA, Barbour JR, Stroud RE, Bouges S, Stephens SL, Spinale FG, Ikonomidis JS. Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J Vasc Res. 2008; 45(6):457-68. PMID: 18434745; PMCID: PMC2574785.
    60. Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer. 2008 Mar 1; 112(5):1096-105. PMID: 18286506.
      View in: PubMed
    61. Ciftçio?lu N, Vejdani K, Lee O, Mathew G, Aho KM, Kajander EO, McKay DS, Jones JA, Stoller ML. Association between Randall's plaque and calcifying nanoparticles. Int J Nanomedicine. 2008; 3(1):105-15. PMID: 18488421; PMCID: PMC2526355.
    62. Scheuring RA, Jones JA, Polk JD. Human spaceflight health systems for the Constellation Project. Aviat Space Environ Med. 2007 Dec; 78(12):1179-80. PMID: 18064927.
      View in: PubMed
    63. Crucian B, Lee P, Stowe R, Jones J, Effenhauser R, Widen R, Sams C. Immune system changes during simulated planetary exploration on Devon Island, high arctic. BMC Immunol. 2007; 8:7. PMID: 17521440; PMCID: PMC1890299.
    64. Maliev V, Popov D, Casey RC, Jones JA. Mechanisms of action for an anti-radiation vaccine in reducing the biological impact of high dose and dose-rate, low-linear energy transfer radiation exposure. Radiats Biol Radioecol. 2007 May-Jun; 47(3):286-91. PMID: 17867496.
      View in: PubMed
    65. Pietrzyk RA, Jones JA, Sams CF, Whitson PA. Renal stone formation among astronauts. Aviat Space Environ Med. 2007 Apr; 78(4 Suppl):A9-13. PMID: 17511294.
      View in: PubMed
    66. Jones JA, McCarten M, Manuel K, Djojonegoro B, Murray J, Feiversen A, Wear M. Cataract formation mechanisms and risk in aviation and space crews. Aviat Space Environ Med. 2007 Apr; 78(4 Suppl):A56-66. PMID: 17511300.
      View in: PubMed
    67. Barr YR, Bacal K, Jones JA, Hamilton DR. Breast cancer and spaceflight: risk and management. Aviat Space Environ Med. 2007 Apr; 78(4 Suppl):A26-37. PMID: 17511296.
      View in: PubMed
    68. Jones JA, Kirkpatrick AW, Hamilton DR, Sargsyan AE, Campbell M, Melton S, Barr YR, Dulchavsky SA. Percutaneous bladder catheterization in microgravity. Can J Urol. 2007 Apr; 14(2):3493-8. PMID: 17466154.
      View in: PubMed
    69. Stepaniak PC, Ramchandani SR, Jones JA. Acute urinary retention among astronauts. Aviat Space Environ Med. 2007 Apr; 78(4 Suppl):A5-8. PMID: 17511293.
      View in: PubMed
    70. Kirkpatrick AW, Jones JA, Sargsyan A, Hamilton DR, Melton S, Beck G, Nicolau S, Campbell M, Dulchavsky S. Trauma sonography for use in microgravity. Aviat Space Environ Med. 2007 Apr; 78(4 Suppl):A38-42. PMID: 17511297.
      View in: PubMed
    71. Jones JA, Riggs PK, Yang TC, Pedemonte CH, Clarke MS, Feeback DL, Au WW. Ionizing radiation-induced bioeffects in space and strategies to reduce cellular injury and carcinogenesis. Aviat Space Environ Med. 2007 Apr; 78(4 Suppl):A67-78. PMID: 17511301.
      View in: PubMed
    72. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21. PMID: 16622120.
      View in: PubMed
    73. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006 Jun; 14(6):505-15. PMID: 16601950.
      View in: PubMed
    74. Jones JA, Jennings R, Pietryzk R, Ciftcioglu N, Stepaniak P. Genitourinary issues during spaceflight: a review. Int J Impot Res. 2005 Dec; 17 Suppl 1:S64-7. PMID: 16391546.
      View in: PubMed
    75. Rafiq A, Broderick TJ, Williams DR, Doarn CR, Jones JA, Merrell RC. Assessment of simulated surgical skills in parabolic microgravity. Aviat Space Environ Med. 2005 Apr; 76(4):385-91. PMID: 15828640.
      View in: PubMed
    76. Kirkpatrick AW, Campbell MR, Jones JA, Broderick TJ, Ball CG, McBeth PB, McSwain NE, Hamilton DR, Holcomb JB. Extraterrestrial hemorrhage control: terrestrial developments in technique, technology, and philosophy with applicability to traumatic hemorrhage control in long-duration spaceflight. J Am Coll Surg. 2005 Jan; 200(1):64-76. PMID: 15631922.
      View in: PubMed
    77. Sargsyan AE, Hamilton DR, Jones JA, Melton S, Whitson PA, Kirkpatrick AW, Martin D, Dulchavsky SA. FAST at MACH 20: clinical ultrasound aboard the International Space Station. J Trauma. 2005 Jan; 58(1):35-9. PMID: 15674147.
      View in: PubMed
    78. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20. PMID: 15470214.
      View in: PubMed
    79. Viegas SF, Williams D, Jones J, Strauss S, Clark J. Physical demands and injuries to the upper extremity associated with the space program. J Hand Surg Am. 2004 May; 29(3):359-66. PMID: 15140472.
      View in: PubMed
    80. Rawat N, Connor CW, Jones JA, Kozlovskaya IB, Sullivan P. The correlation between aerobic fitness and motion sickness susceptibility. Aviat Space Environ Med. 2002 Mar; 73(3):216-8. PMID: 11908888.
      View in: PubMed
    81. Cucinotta FA, Manuel FK, Jones J, Iszard G, Murrey J, Djojonegro B, Wear M. Space radiation and cataracts in astronauts. Radiat Res. 2001 Nov; 156(5 Pt 1):460-6. PMID: 11604058.
      View in: PubMed
    82. Hussain MH, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M, Jones J, Balcerzak SP, Crawford ED, Grossman HB. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol. 2001 Jan; 165(1):56-60; discussion 60-1. PMID: 11125363.
      View in: PubMed
    83. Jones JA, Hart SF, Baskin DS, Effenhauser R, Johnson SL, Novas MA, Jennings R, Davis J. Human and behavioral factors contributing to spine-based neurological cockpit injuries in pilots of high-performance aircraft: recommendations for management and prevention. Mil Med. 2000 Jan; 165(1):6-12. PMID: 10658420.
      View in: PubMed
    84. Jones JA, Johnston S, Campbell M, Miles B, Billica R. Endoscopic surgery and telemedicine in microgravity: developing contingency procedures for exploratory class spaceflight. Urology. 1999 May; 53(5):892-7. PMID: 10223479.
      View in: PubMed
    85. de Riese C, Crabtree WN, de Riese W, Jones JA, Pastor J, Haupt G, Foster RS, Donohue JP, Senge T. Impact of the preparation technique on DNA content measured by image analysis in early stage human testis cancer. Int Urol Nephrol. 1995; 27(5):603-13. PMID: 8775046.
      View in: PubMed
    86. Gleason PE, Jones JA, Regan JS, Salvas DB, Eble JN, Lamph WW, Vlahos CJ, Huang WL, Falcone JF, Hirsch KS. Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia. J Urol. 1993 Jun; 149(6):1586-92. PMID: 7684794.
      View in: PubMed
    87. Ganesan GS, Cory D, Mitchell ME, Jones JA. Magnetic resonance imaging of penile rhabdomyosarcoma. Br J Radiol. 1992 Feb; 65(770):175-8. PMID: 1540812.
      View in: PubMed
    88. Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990 Aug; 144(2 Pt 1):287-91; discussion 291-2. PMID: 2165181.
      View in: PubMed
    89. Don S, Kopecky KK, Filo RS, Leapman SB, Thomalla JV, Jones JA, Klatte EC. Duplex Doppler US of renal allografts: causes of elevated resistive index. Radiology. 1989 Jun; 171(3):709-12. PMID: 2655003.
      View in: PubMed
    JONES's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _